Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company's current EPS (TTM) is 16,66 €. In 2022 the company made an earnings per share (EPS) of 18,94 € an increase over its 2021 EPS that were of 9,41 €.